Vanguard Group Inc. Has $47.07 Million Stake in Geron Corporation $GERN

Vanguard Group Inc. raised its stake in shares of Geron Corporation (NASDAQ:GERN) by 3.6% in the 4th quarter, Holdings Channel reports. The firm owned 35,660,969 shares of the biopharmaceutical company’s stock after purchasing an additional 1,237,844 shares during the quarter. Vanguard Group Inc. owned 0.06% of Geron worth $47,072,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. 55 North Private Wealth LLC bought a new position in Geron during the 4th quarter worth $29,000. Swiss Life Asset Management Ltd increased its position in Geron by 73.6% in the 3rd quarter. Swiss Life Asset Management Ltd now owns 26,371 shares of the biopharmaceutical company’s stock valued at $36,000 after buying an additional 11,182 shares in the last quarter. Fisher Asset Management LLC bought a new stake in Geron in the 3rd quarter valued at about $37,000. Franklin Resources Inc. bought a new stake in Geron in the 3rd quarter valued at about $45,000. Finally, Walleye Capital LLC acquired a new position in Geron during the 2nd quarter valued at about $56,000. 73.71% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Geron in a research note on Monday, April 27th. TD Cowen reaffirmed a “buy” rating on shares of Geron in a report on Thursday, January 29th. Two investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $2.50.

Geron Stock Down 7.9%

Shares of NASDAQ:GERN opened at $1.29 on Friday. Geron Corporation has a 52-week low of $1.04 and a 52-week high of $2.01. The firm has a fifty day moving average of $1.56 and a 200 day moving average of $1.44. The firm has a market capitalization of $827.56 million, a PE ratio of -11.73 and a beta of 0.68. The company has a debt-to-equity ratio of 0.52, a quick ratio of 4.96 and a current ratio of 6.78.

Geron (NASDAQ:GERN) last posted its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.03) by $0.02. The business had revenue of $51.84 million during the quarter, compared to analyst estimates of $50.59 million. Geron had a negative net margin of 35.48% and a negative return on equity of 23.31%. As a group, research analysts anticipate that Geron Corporation will post -0.02 EPS for the current fiscal year.

Geron Company Profile

Geron Corporation (NASDAQ: GERN) is a clinical-stage biotechnology company dedicated to developing and commercializing novel treatments that target telomerase, an enzyme critical to cancer cell immortality. The company’s research is focused on hematologic malignancies and solid tumors, with a pipeline designed to address diseases that have historically had limited therapeutic options.

The lead product candidate, imetelstat, is a first-in-class telomerase inhibitor currently in Phase II and Phase III clinical trials for myelofibrosis and myelodysplastic syndromes.